मैट्रिक्स
 
 
सुवेन लाइफ साइंसेस > कंपनी इतिहास > Pharmaceuticals > कंपनी इतिहास का सुवेन लाइफ साइंसेस - बीएसई: 530239, NSE: SUVEN

सुवेन लाइफ साइंसेस

बीएसई: 530239  |  NSE: SUVEN  |  ISIN: INE495B01038  |  Pharmaceuticals

कंपनी इतिहास - सुवेन लाइफ साइंसेस
Brief History and business of the Company
 
 Suven Pharmaceuticals Limited was promoted in 1989 by
 Mr.Jasti Venkateswarlu and Mrs. Jasti Sudha Rani for the
 manufacture of bulk drugs and drug intermediates. The
 Company was incorporated as a Private Limited Company on
 9th March, 1989 in the state of Andhra Pradesh.
 Subsequently on 4th January, 1995 it was converted into a
 Public Limited Company in terms of special resolution dated
 25.11.94 U/s. 31(1)/44 of Companies Act.
 
            - The Company deveops and manufactures drug intermediates,
 under
                contract from the drug's global patent holders.
 
 2000 
 
            - The Company has entered into agreement with NSDL and
 CDSL for
              dematerialisation of shares.
           
            - Company bags export orders of Rs 21 cr
 
 2001 - Borregaard Industries Ltd, Norway, acquires 15% stake in the
 company
 
 2002- An accident occurred at the company's Suryapet Unit AS when a
 transporters vehicle entered the factory premises on November 17,
 2002
 
 -Pfizer Ltd and Suven Pharmaceuticals Ltd have tied up with the
 Bombay College of Pharmacy to set up an academy for clinical
 excellence (ACE) , in Mumbai.
 
 2003-Borregaard Industries Ltd, a Norwegean pharma player has
 offloaded its entire 17.05 per cent stake ( 7.50 lakh equity shares)
 in Suven Life Sciences Ltd 
 
 -Suven Life Sciences USA LLC a wholly owned subsidiary of Suven
 Pharmaceuticals Ltd has acquired Synthon Chiragenics Corporation New
 Jersey USA
 
 2004
 
 -Suven Life Sciences Ltd has informed the stock exchanges that its
 shareholders at the extraordinary general meeting held on Jan 05 have
 approved the sub-division of equity shares into face value of Rs 2
 each from the face value of Rs 10 each.
 
 -Suven Life Sciences BoD approves preferential shares issue
 
 -Suven Life Sciences Ltd has said that its board of directors on Jan
 19 has allotted 30 lakh equity shares of face value of Rs 2 each on
 preferential basis to four investors. While Emerging Markets
 Management LLC was allotted 10 lakh shares, Aeneas Portfolio Company
 LP 8.75 lakh shares, Commonwealth Equity Fund Ltd, a sub-account of
 Batterymarch Financial Management Inc, 6.25 lakh shares and Mr
 Rambabu Chirumamilla was given 5 lakh shares.
 
 -Two units of Suven Life (Suryapet & Jeedimetla) get ISO
 confirmation
 
 2007
 
 - Suven Life Sciences Ltd (Suven) on November 27, 2007 has announced
 that the European Patent Office (EPO) granted Two Patents, 1523486
 and 1581538 to Suven and are valid until June 2022.
 
 -The Company has issued Bonus Shares in the Ratio of 1:1.
 
 - The Company has splits its face value from Rs2/- to Rs1/-.
 
 2009
 
 - Suven Life Sciences has secured two U.S. patents relating to new
 chemical entities (NCEs) for treatment of disorders associated with
 neurodegenerative diseases
 
 - Suven Life Sciences Ltd (Suven) announces today that the European
 Patent Office (EPO) has Issued 3 new Patents: EP1537113, EP1704154
 and EP1856132 corresponding to three New Chemical Entities (NCEs) for
 the treatment of disorders associated with Neurodegenerative diseases
 and these Patents are valid until 2022,23 and 24 respectively.
 
 2010
 
 -Suven Secures Two product patents in China and Russia
 
 -Suven Life Sciences secures 5th Product Patent from US patent office
 for their NCE to treat Central Nervous System
 
 -Suven Life Sciences bagged the eight product patent from European
 Patent Office (EPO) for their NCE to treat Central Nervous System
 (CNS) disorders. 
 
 -Suven Life Secures Three Australian Patents on NCEs
 
 -Suven gets two patents from Japanese Patent Office for NCE's
 
 2011
 
 -Suven's Unit-III receives US FDA Acceptance
 
 -Suven Life Sciences secures 7 Product Patents for their NCEs in
 several key markets in the world
 
 -Suven Life Sciences bags Bio-Excellence Award at Bangalore India Bio
 2011
 
 -Suven Life Sciences secures 2 Product Patents for their NCEs in the
 key markets in the world
 
 -Suven Life Sciences bags Pharmexcil's Gold Patent Award
 
 2012
 
 -Suven Life Sciences secures 3 Product Patents for their NCEs in
 Mexico and USA
 
 -Suven Life Sciences gets 4 Product Patents in Japan, Australia,
 Europe and Eurasia
 
 -Suven Life Sciences bags Pharmexcil's Platinum Patent Award
 
 -Suven Life Sciences secures 5 Product Patents for their NCEs in
 China & Korea.
 
 
 2013
 
 - Suven Life Sciences bags 4 Product Patents for their NCEs in China,
 Mexico and New Zealand
 
 - Suven Life secures three Product Patents for their NCEs in Canada
 and Eurasia
 
 - Suven Life secures two (2) Product Patents for their NCEs in
 Europe
 
 - The Company has recommended Dividend Re. 30 paisa per equity share
 of face value of Re. 1/-.
  
 
 2014
 
 - SUVENS PASHAMYLARAMS UNIT RECEIVES US FDA ACCEPTANCE
 
 - Suven Life Sciences bags Pharmexcils 'Gold Patent Award' for NCEs
 and 'Outstanding Export Performance Award' for Contract Research and
 Manufacturing.
 
 - Suven Life Sciences awarded Forbes Asia's Best Under A Billion
 Award
 
 2015
 - Suven initiated Multiple Ascending Dose (MAD) studies in Phase 1
 clinical Trial for their investigational compound SUVN-G3031
 - Suven Life Sciences bags Pharmexcils Gold Patent Award
 
 
स्रोत: रेलीगरे टेचनोवा

न्यूज़ फ़्लैश

  • MARKET CUES : FIIs ने कैश में `750 Cr की खरीदारी की
  • MARKET CUES : DIIs ने कैश में `703 Cr की बिकवाली की
  • MARKET CUES : FIIs ने F&O में `725 Cr की बिकवाली की
  • MARKET CUES : इंडेक्स फ्यूचर्स में `661 Cr की खरीदारी की
  • MARKET CUES : इंडेक्स ऑप्शंस में `861 Cr की बिकवाली की
  • MARKET CUES : स्टॉक फ्यूचर्स में `681 Cr की बिकवाली की
  • CS ON INFOSYS : Underperform रेटिंग, लक्ष्य बढ़ाकर `720/Sh
  • JEFFERIES ON INFOSYS : BUY रेटिंग, लक्ष्य घटाकर `915/Sh
  • CITI ON INFOSYS : BUY रेटिंग, लक्ष्य `900/Sh
  • UBS ON INFOSYS : Neutral रेटिंग, लक्ष्य `900/Sh

अभी देखें

ओवरड्राइव

OUR WINNING PICKS

DID YOU INVEST?

INTRADAY PICKS!

(August 06, 2018)

AT (Rs)



GAIN (Rs)

ALL TIME WINNERS

RECO PRICE

PEAK PRICE

OUR PACKAGES

Super Combo

Powerful mix of both trader and investor packs with timely expert advice.

Technical

Designed especially for traders looking to tap the profit opportunities of volatile markets.

Fundamental

For all investors looking to unearth stocks that are poised to move.